Several members of an in-depth investigated family of pyrazolo[3,4-d]pyrimidines by Schenone’s and Botta’s research groups developed as Src inhibitors [276,277,278] resulted active in preclinical models of NB [279,280,281]. The gene discussed is SRC; the disease is neuroblastoma.